Regulus Therapeutics (NASDAQ:RGLS) shares traded down -8.86% during most recent session. Wall Street analysts covering the stock are projecting that the stock will reach $0.67 within the next 52-weeks. The mean target projections are based on 5 opinions. Since analyst price targets calculations are subjective, there often can be wide range of targets from various analysts.
Having a look in a broader way analysts from brokerage firms on the street with an extensive view have high price target of Regulus Therapeutics (NASDAQ:RGLS) at $1 and with a conformist view have low price target of $0.35 while the stock’s latest closing price was $0.33. This is the consensus price target based on the analysts polled by Thomson Reuters’ First Call, the average is taken from the individual analysts which provided targets and are short term projections for the 12 months.
The ABR is the calculated average of the actual recommendations (strong buy, hold, sell etc.) made by the brokerage firms for the given stock. Currently shares of Regulus Therapeutics (NASDAQ:RGLS) have an average brokerage recommendation (ABR) of 3 number of Recs in ABR is 5 however the company’s industry rank by ABR is out of 255. Industries are ranked based on the average broker recommendation of each company belong to this industry. A low number means that brokers and analysts expect that the industry outperform the market.
Outperform is an analyst recommendation which means that a stock is expected to do slightly better than the market return. Outperform is also known as “moderate-buy” or “over-weight” or “accumulate”. Whereas Underperform can also be taken in with “moderate sell” or “under-weight” or “weak-hold”.
For Regulus Therapeutics (NASDAQ:RGLS) out of the analyst recommendations 2 analysts recommend stock a Buy, 0 rate the stock Outperform, 4 analysts recommend to Hold the stock, 0 rate Underperform and 0 analysts recommend the stock a Sell.
The Average True Range (ATR) is an indicator that measures volatility, it was developed by J. Welles Wilder. Typically, the Average True range (ATR) is based on 14 periods and can be calculated on an intra-day, daily, weekly or monthly basis. Because there must be a beginning, the first TR value is simply the High minus the Low, and the first 14-day ATR is the average of the daily TR values for the last 14 days. Regulus Therapeutics (NASDAQ:RGLS)’s ATR-14 is at 0.07, while its weekly volatility is at 15.97% and monthly volatility is at 9.32%. A stock experiencing a high level of volatility has a higher ATR, and a low volatility stock has a lower ATR. The ATR may be used by market technicians to enter and exit trades, and it is a useful tool to add to a trading system. It was created to allow traders to more accurately measure the daily volatility of an asset by using simple calculations. The indicator does not indicate the price direction, rather used primarily to measure volatility caused by gaps and limit up or down moves. The ATR is fairly simple to calculate and only needs historical price data.
RSI is an extremely popular momentum indicator, the Relative Strength Index (RSI) also developed by J. Welles Wilder, is a momentum oscillator that measures the speed and change of price movements. RSI value of Regulus Therapeutics (NASDAQ:RGLS) is 18.79. RSI oscillates between zero and 100. Traditionally, and according to Wilder, RSI is considered overbought when above 70 and oversold when below 30. Signals can also be generated by looking for divergences, failure swings, and centerline crossovers. RSI can also be used to identify the general trend. The default time frame for comparing up periods to down periods is 14, as in 14 trading days.
Shares of Regulus Therapeutics (NASDAQ:RGLS) has a market capitalization of $70.5 Million and its number of outstanding shares are 214.86 Million. During previous trade 3.14 Million shares of Regulus Therapeutics (NASDAQ:RGLS) exchanged hands whereas on average almost 420.59 Million shares has been traded.